Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $1.4 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Assets fell 69.01% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 69.01%. This contributed to the annual value of $1.4 million for FY2025, which is 69.01% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $1.4 million for FY2025, which was down 69.01% from $4.5 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Other Non-Current Assets high stood at $4.5 million for FY2024, and its period low was $218,000 during FY2022.
  • Its 3-year average for Other Non-Current Assets is $3.0 million, with a median of $3.3 million in 2023.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Other Non-Current Assets soared by 1,394.95% in 2023 and then plummeted by 69.01% in 2025.
  • Arrowhead Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $272,000 in 2021, then dropped by 19.85% to $218,000 in 2022, then spiked by 1,394.95% to $3.3 million in 2023, then surged by 37.53% to $4.5 million in 2024, then tumbled by 69.01% to $1.4 million in 2025.